

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

Figure 1A




Figure 1B




Figure 1C




Figure 1D




Figure 1E

Sensitization of HCT 116 and HCT 15 colon cancer cells to chemotherapeutic agents by PDTTC (70 $\mu$ M) or vitamin E (3 mM)				
Cell line	Drug	IC <sub>50</sub> ( $\mu$ M) <sup>a</sup>		
		- Antioxidant	+ PDTTC	+ vitamin E
HCT 116	5FU	3.8 ( $\pm$ 0.21)	1.5 ( $\pm$ 0.29)	1.7 ( $\pm$ 0.20)
	Doxorubicin	0.32 ( $\pm$ 0.07)	0.09 ( $\pm$ 0.08)	0.13 ( $\pm$ 0.05)
HCT 15	5FU	11.4 ( $\pm$ 0.11)	1.01 ( $\pm$ 0.09)	1.4 ( $\pm$ 0.10)
	Doxorubicin	1.51 ( $\pm$ 0.07)	0.11 ( $\pm$ 0.05)	0.17 ( $\pm$ 0.04)

<sup>a</sup>The concentration of 5-FU or doxorubicin required to reduce soft agar colony formation by 50% ( $\pm$ s.e.m.). Underscored: significantly different from -antioxidant group ( $P < 0.01$ ), as determined by analysis of variance with multiple comparison adjustment.

Figure 2A





Figure 2B




Figure 3A Western blot




Figure 3B Northern blot




Figure 3C








Figure 4A



102290" 98067260

Figure 4B




Figure 4C




Figure 4D




Figure 4E





Figure 4F





FO2230-98064260





Figure 5A



**FIGURE 5B**

09779086-062001  
102290-9806/250




FIGURE 6A



FOI2290-98064460




FIGURE 6B

FD-290" 5806/260




Figure 7A

097906-06201




Figure 7B

102290-9806460





Figure 7C


Figure 7D

Blocked antisera




DAPD

Control



C/EBP $\beta$

PDTC



DAPD C/EBP $\beta$




FIGURE 8A





FIGURE 8B

Figure 9A




Figure 9B Trypsin cleavage



FO2290" 98067760



Figure 9C



102290" 9806/260

Figure 10A





Figure 10B



0979065-06201  
FO2290-98064650

FIGURE—11

Carboxymethylation of PP2Ac is Inhibited by  
Antioxidants





FIGURE 12

Antioxidants Inhibit Methyltransferase Activity Against PP2Ac



## PDTC Inhibits PP2A, but not PP1, Activity




Figure 13

Figure 14

